Surgery Vs. Radiotherapy in Patients with Uveal Melanoma : Analysis of the SEER Database Using Propensity Score Matching and Weighting

Overview

Journal Strahlenther Onkol

Specialties Oncology
Radiology

Date 2017 Sep 8

PMID 28879443

Citations 7

Authors

Bum-Sup Jang

Ji Hyun Chang

Sohee Oh

Yu Jin Lim

Il Han Kim

Affiliations

Soon will be listed here.

Abstract

Background: The treatment modalities for uveal melanoma (UM) include surgery and radiotherapy (RT). The utilization of RT as a strategy for organ preservation has been increasing, but the survival difference between the two aforementioned treatment modalities has not been reported.

Methods: An observational and cohort study was performed using a propensity score with an already existing public database. Patients diagnosed with UM within the period from 2004-2013 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. One-to-one matching and inverse probability of treatment weighting (IPTW) using the propensity score were used to estimate and compare survival rates.

Results: Overall, 3291 patients were treated: 2503 received RT only (RT group) and 788 received surgical resection only (surgery group). The RT group had an improved crude 5‑year overall survival (OS) rate compared with the surgery group (76% vs. 60%, P < 0.001), and an improved 5‑year melanoma-specific survival (MSS) rate (89% vs. 73%, P < 0.001). Compared to the surgery group, the RT group was associated with improved OS (hazard ratio [HR] 0.52, 95% confidence interval [CI] 0.38-0.73, P < 0.001) and MSS (HR 0.48, 95% CI 0.35-0.65, P < 0.001) in the matched cohort. The survival benefit of the RT group maintained after adjustment with IPTW, both in OS and MSS.

Conclusions: To our knowledge, the present study was the first to demonstrate the survival difference between the two treatment modalities for UM using both the propensity score matching and weighting methods with the SEER database. The current study suggests that RT may provide a survival advantage over surgery in the treatment of UM.

Citing Articles

A prognostic nomogram for the cancer-specific survival rate of choroidal melanoma using the Surveillance, Epidemiology, and End Results database.

Cao X, Zeng J, Ou Y, Chen J, Lyu J, Zhou Q Front Med (Lausanne). 2024; 11:1392336.

PMID: 38818391 PMC: 11137212. DOI: 10.3389/fmed.2024.1392336.

Prognostic Factors and Nomograms for Overall and Cancer-Specific Survival of Patients with Uveal Melanoma without Metastases: A SEER Analysis of 4119 Cases.

Liu X, Liu C, Shang Y, Yang L, Tan F, Lv Y J Ophthalmol. 2022; 2022:1874336.

PMID: 36157683 PMC: 9492333. DOI: 10.1155/2022/1874336.

Construction and validation of a pyroptosis-related gene signature associated with the tumor microenvironment in uveal melanoma.

Zhang F, Deng Y, Wang D, Wang S Sci Rep. 2022; 12(1):1640.

PMID: 35102195 PMC: 8803850. DOI: 10.1038/s41598-022-05599-9.

Primary Sites of Uveal Melanoma Associated with Distinct Survival Outcomes and Clinicopathological Features: A SEER Population-Based Study of 4359 Cases.

Liang X, Rong Y, Wang J, Zhang H Int J Gen Med. 2021; 14:5221-5232.

PMID: 34512005 PMC: 8427688. DOI: 10.2147/IJGM.S328910.

The Influence of Marital Status on the Survival of Patients with Uveal Melanoma.

Cai W, Fan J, Shen T, Yu J J Ophthalmol. 2021; 2020:7012940.

PMID: 33489340 PMC: 7803291. DOI: 10.1155/2020/7012940.

References

Damato B . Legacy of the collaborative ocular melanoma study. Arch Ophthalmol. 2007; 125(7):966-8. DOI: 10.1001/archopht.125.7.966. View

Shields C, Kaliki S, Furuta M, Fulco E, Alarcon C, Shields J . American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients. Ophthalmology. 2013; 120(10):2066-71. DOI: 10.1016/j.ophtha.2013.03.012. View

Egger E, Schalenbourg A, Zografos L, BERCHER L, Boehringer T, Chamot L . Maximizing local tumor control and survival after proton beam radiotherapy of uveal melanoma. Int J Radiat Oncol Biol Phys. 2001; 51(1):138-47. DOI: 10.1016/s0360-3016(01)01560-7. View

Kapoor A, Beniwal V, Beniwal S, Mathur H, Kumar H . Management of uveal tract melanoma: A comprehensive review. J Egypt Natl Canc Inst. 2016; 28(2):65-72. DOI: 10.1016/j.jnci.2016.02.003. View

Seddon J, Gragoudas E, Albert D, Hsieh C, Polivogianis L, Friedenberg G . Comparison of survival rates for patients with uveal melanoma after treatment with proton beam irradiation or enucleation. Am J Ophthalmol. 1985; 99(3):282-90. DOI: 10.1016/0002-9394(85)90357-5. View

Singh A, Shields C, Shields J . Prognostic factors in uveal melanoma. Melanoma Res. 2001; 11(3):255-63. DOI: 10.1097/00008390-200106000-00007. View

Abrams M, Gagne N, Melhus C, Mignano J . Brachytherapy vs. external beam radiotherapy for choroidal melanoma: Survival and patterns-of-care analyses. Brachytherapy. 2016; 15(2):216-23. DOI: 10.1016/j.brachy.2015.12.001. View

Nathan P, Cohen V, Coupland S, Curtis K, Damato B, Evans J . Uveal Melanoma UK National Guidelines. Eur J Cancer. 2015; 51(16):2404-12. DOI: 10.1016/j.ejca.2015.07.013. View

Gragoudas E, Li W, Goitein M, Lane A, Munzenrider J, Egan K . Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. Arch Ophthalmol. 2002; 120(12):1665-71. DOI: 10.1001/archopht.120.12.1665. View

10.

Caujolle J, Mammar H, Chamorey E, Pinon F, Herault J, Gastaud P . Proton beam radiotherapy for uveal melanomas at nice teaching hospital: 16 years' experience. Int J Radiat Oncol Biol Phys. 2009; 78(1):98-103. DOI: 10.1016/j.ijrobp.2009.07.1688. View

11.

Affeldt J, Minckler D, Azen S, Yeh L . Prognosis in uveal melanoma with extrascleral extension. Arch Ophthalmol. 1980; 98(11):1975-9. DOI: 10.1001/archopht.1980.01020040827006. View

12.

Austin P, Stuart E . Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015; 34(28):3661-79. PMC: 4626409. DOI: 10.1002/sim.6607. View

13.

Sandinha M, Farquharson M, McKay I, Roberts F . Monosomy 3 predicts death but not time until death in choroidal melanoma. Invest Ophthalmol Vis Sci. 2005; 46(10):3497-501. DOI: 10.1167/iovs.05-0613. View

14.

Kleineidam M, Guthoff R, Bentzen S . Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques. Radiother Oncol. 1993; 28(2):148-56. DOI: 10.1016/0167-8140(93)90007-u. View

15.

Dunavoelgyi R, Dieckmann K, Gleiss A, Sacu S, Kircher K, Georgopoulos M . Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. Int J Radiat Oncol Biol Phys. 2010; 81(1):199-205. DOI: 10.1016/j.ijrobp.2010.04.035. View

16.

Austin P . An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011; 46(3):399-424. PMC: 3144483. DOI: 10.1080/00273171.2011.568786. View

17.

. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006; 124(12):1684-93. DOI: 10.1001/archopht.124.12.1684. View

18.

Sarici A, Pazarli H . Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2012; 251(1):285-94. DOI: 10.1007/s00417-012-2144-z. View

19.

Gragoudas E, Egan K, Seddon J, Glynn R, Walsh S, Finn S . Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991; 98(3):383-9; discussion 390. DOI: 10.1016/s0161-6420(91)32285-1. View

20.

Singh A, Turell M, Topham A . Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011; 118(9):1881-5. DOI: 10.1016/j.ophtha.2011.01.040. View